Literature DB >> 18468013

Does the use of a volatile anesthetic regimen attenuate the incidence of cardiac events after vascular surgery?

S G De Hert1, D Longrois, H Yang, L A Fleisher.   

Abstract

OBJECTIVE: To compare the effects of a volatile anesthetic to a non-volatile anesthetic regimen on the incidence of postoperative cardiac events, including the postoperative elevation of troponin I values after arterial vascular surgery in high risk patients.
DESIGN: Retrospective analysis of data of a phase II study that compared the Na+/H+ exchanger type II inhibitor, zoniporide to placebo on the occurrence of cardiac events.
SETTING: Multicenter study conducted in 105 sites throughout the United States, South America, Europe and Asia. PARTICIPANTS: 784 subjects scheduled for urgent or elective major arterial vascular surgery and a history of at least 3 of the following: age > or = 65 years, hypertension, documented stroke or transient ischemic attack, previous myocardial infarction, active angina pectoris diabetes mellitus, congestive heart failure, or symptomatic cardiac arrhythmia.
INTERVENTIONS: Type of anesthesia was retrospectively retrieved from the database and patients were subdivided in two groups: inhalational (group A) vs non-inhalational anesthetic regimen (group B). Incidence of postoperative cardiac events was compared between the two groups.
MEASUREMENTS AND MAIN RESULTS: The incidence of postoperative cardiac events was not different between the two groups. Maximum postoperative troponin I levels was not different between the two groups in the total population and in the patients undergoing peripheral arterial surgery. In patients undergoing aortic surgery the incidence of elevated troponin levels higher than 1.5 and 4 ng x mL(-1) tended to be lower in group A than in group B in the aortic surgery (28% vs 18% and 30% vs 20% respectively) but this difference did not reach statistical significance.
CONCLUSION: The results of this hypothesis-generating study suggest that potential beneficial effects on extent of postoperative myocardial damage in high risk patients undergoing arterial surgery will probably be more apparent in abdominal aortic surgery than in peripheral vascular surgery. Further sufficiently powered studies using a standardized protocol should now be performed to definitively address this question.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468013

Source DB:  PubMed          Journal:  Acta Anaesthesiol Belg        ISSN: 0001-5164


  5 in total

1.  Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial.

Authors:  Joseph L Blackshear; Donald E Cutlip; Gary S Roubin; Michael D Hill; Pierre P Leimgruber; Richard J Begg; David J Cohen; John F Eidt; Craig R Narins; Ronald J Prineas; Stephen P Glasser; Jenifer H Voeks; Thomas G Brott
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

2.  Volatile anaesthetics and cardiac protection in abdominal surgery.

Authors:  Jasminka Kopić
Journal:  Wien Klin Wochenschr       Date:  2015-07-10       Impact factor: 1.704

Review 3.  Anaesthetics as cardioprotectants: translatability and mechanism.

Authors:  C Kikuchi; S Dosenovic; M Bienengraeber
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

4.  Cardioprotective effect of sevoflurane in patients with coronary artery disease undergoing vascular surgery.

Authors:  Ahmed S Bassuoni; Yasser M Amr
Journal:  Saudi J Anaesth       Date:  2012-04

5.  Anaesthesia and multimodality intraoperative neuromonitoring in carotid endarterectomy. Chronological evolution and effects on intraoperative neurophysiology.

Authors:  Ana Mirallave Pescador; Pedro Javier Pérez Lorensu; Ángel Saponaro González; Beneharo Darias Delbey; José Luis Pérez Burkhardt; Roberto Ucelay Gómez; Enrique Francisco González Tabares; Zeina Ibrahim Achi; Christian Salvador Guerrero Ramírez; Carol Elizabeth Padrón Encalada; Alejandro Jiménez Sosa; Julio Plata Bello
Journal:  J Clin Monit Comput       Date:  2021-01-03       Impact factor: 1.977

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.